Glucocorticoids

Melissa Northcott; Eric F. Morand

doi:10.1016/B978-0-12-820583-9.00006-3

Glucocorticoids

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review

Abstract

Glucocorticoids (GCs) were first used for the treatment of inflammatory disease in the 1950s and have been heavily relied on for systemic lupus erythematosus (SLE) management across the seven decades since. Their potent antiinflammatory and immunosuppressive properties and rapid onset of action make GCs effective in suppressing SLE disease activity in many cases, and their use can be life or organ saving in patients with severe disease. However, their predictable and dose-dependent adverse effects make GCs a less than optimal treatment in SLE, especially for long-term use, and minimization is therefore a goal of SLE management. The clinical use of GCs in SLE, mechanisms of action, and adverse effects will be discussed in this chapter.

Original language	English
Title of host publication	Lahita’s Systemic Lupus Erythematosus
Editors	Robert G. Lahita, Karen H. Costenbader, Richard Bucala, Susan Manzi, Munther A. Khamashta
Place of Publication	London UK
Publisher	Elsevier - Mosby
Chapter	38
Pages	611-622
Number of pages	12
Edition	6th
ISBN (Electronic)	9780128205839
DOIs	https://doi.org/10.1016/B978-0-12-820583-9.00006-3
Publication status	Published - 2021

Keywords

Corticosteroids
Glucocorticoids
Systemic lupus erythematosus
Treatment

Access to Document

10.1016/B978-0-12-820583-9.00006-3

Cite this

@inbook{81b9f6ac9606425b8f92f98c39c845a5,

title = "Glucocorticoids",

abstract = "Glucocorticoids (GCs) were first used for the treatment of inflammatory disease in the 1950s and have been heavily relied on for systemic lupus erythematosus (SLE) management across the seven decades since. Their potent antiinflammatory and immunosuppressive properties and rapid onset of action make GCs effective in suppressing SLE disease activity in many cases, and their use can be life or organ saving in patients with severe disease. However, their predictable and dose-dependent adverse effects make GCs a less than optimal treatment in SLE, especially for long-term use, and minimization is therefore a goal of SLE management. The clinical use of GCs in SLE, mechanisms of action, and adverse effects will be discussed in this chapter.",

keywords = "Corticosteroids, Glucocorticoids, Systemic lupus erythematosus, Treatment",

author = "Melissa Northcott and Morand, {Eric F.}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

doi = "10.1016/B978-0-12-820583-9.00006-3",

language = "English",

pages = "611--622",

editor = "Lahita, {Robert G.} and Costenbader, {Karen H.} and Richard Bucala and Susan Manzi and Khamashta, {Munther A.}",

booktitle = "Lahita{\textquoteright}s Systemic Lupus Erythematosus",

publisher = "Elsevier - Mosby",

edition = "6th",

}

TY - CHAP

T1 - Glucocorticoids

AU - Northcott, Melissa

AU - Morand, Eric F.

PY - 2021

Y1 - 2021

N2 - Glucocorticoids (GCs) were first used for the treatment of inflammatory disease in the 1950s and have been heavily relied on for systemic lupus erythematosus (SLE) management across the seven decades since. Their potent antiinflammatory and immunosuppressive properties and rapid onset of action make GCs effective in suppressing SLE disease activity in many cases, and their use can be life or organ saving in patients with severe disease. However, their predictable and dose-dependent adverse effects make GCs a less than optimal treatment in SLE, especially for long-term use, and minimization is therefore a goal of SLE management. The clinical use of GCs in SLE, mechanisms of action, and adverse effects will be discussed in this chapter.

AB - Glucocorticoids (GCs) were first used for the treatment of inflammatory disease in the 1950s and have been heavily relied on for systemic lupus erythematosus (SLE) management across the seven decades since. Their potent antiinflammatory and immunosuppressive properties and rapid onset of action make GCs effective in suppressing SLE disease activity in many cases, and their use can be life or organ saving in patients with severe disease. However, their predictable and dose-dependent adverse effects make GCs a less than optimal treatment in SLE, especially for long-term use, and minimization is therefore a goal of SLE management. The clinical use of GCs in SLE, mechanisms of action, and adverse effects will be discussed in this chapter.

KW - Corticosteroids

KW - Glucocorticoids

KW - Systemic lupus erythematosus

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85127630996&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-820583-9.00006-3

DO - 10.1016/B978-0-12-820583-9.00006-3

M3 - Chapter (Book)

AN - SCOPUS:85127630996

SP - 611

EP - 622

BT - Lahita’s Systemic Lupus Erythematosus

A2 - Lahita, Robert G.

A2 - Costenbader, Karen H.

A2 - Bucala, Richard

A2 - Manzi, Susan

A2 - Khamashta, Munther A.

PB - Elsevier - Mosby

CY - London UK

ER -

Glucocorticoids

Abstract

Keywords

Access to Document

Other files and links

Cite this